On Feb. 23, the Organization for Economic Co-operation and Development (OECD) Council adopted guidelines for the licensing of genetic inventions. The guidelines present principles and best practices for intellectual property licenses directed to facilitating access to genetic inventions and increasing the dissemination of genetic information derived from those inventions.

Policies informing the principles and best practices include a need to stimulate research through assurance of an adequate return on investment for biotechnology companies; a desire to encourage research by a broad range of scientists, especially those not involved in the conception of fundamental genetic inventions; and a hope that low-income countries will be able to utilize such inventions to further development of a health care system. The stated policies are well-intentioned, and each appears both reasonable and reachable when considered alone. It is the concurrent pursuit of all three that raises issues, which are discussed below.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]